Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy

Author(s): Yan-Bei Ren, Shang-Jun Sun and Shuang-Yin Han*

Volume 24, Issue 1, 2018

Page: [78 - 83] Pages: 6

DOI: 10.2174/1381612824666171227222624

open access plus

Open Access Journals Promotions 2
Abstract

T-cell therapy using genetically engineered T cells modified with either T cell receptor or chimeric antigen receptor holds great promise for cancer immunotherapy. The concerns about its toxicities still remain despite recent successes in clinical trials. Temporal and spatial control of the engineered therapeutic T cells may improve the safety profile of these treatment regimens. To achieve these goals, numerous approaches have been tested and utilized including the incorporation of a suicide gene, the switch-mediated activation, the combinatorial antigen recognition, etc. This review will summarize the toxicities caused by engineered T cells and novel strategies to overcome them.

Keywords: Immunotherapy, Genetically engineered T cells, Chimeric antigen receptor, Gene therapy, T-cell therapy, suicide gene.


© 2024 Bentham Science Publishers | Privacy Policy